4. Branded generics market with Doctors playing a significant role
Source: McKinsey & Co
Physician Pharmacy Payer
Key Influencer
Product brand
(e.g. Storvas)
TypeofBranding
Company brand
(e.g. Ranbaxy
Atorvastatin)
Unbranded
(e.g. Atorvastatin)
INDIA
Poland
China
Russia
Mexico
Brazil
Italy Spain
France
Germany
UK
USA
“BRANDED
GENERICS”
“GENERIC
GENERICS”
5. Source: AIOCD Mar ’14, McKinsey & Co.
30862
75757
189393
-
50,000
1,00,000
1,50,000
2,00,000
Mar '07 Mar '14 Mar '20
(In Crs.)
Large & growing addressable domestic market…
6. Source: IMS 2012, United Nations Department of Economic and Social Affairs
$1,019
$558
$342
$147
$49
$11
$-
$400
$800
$1,200
US Germany UK Brazil China India
Pharmaceutical expenditure per capita in 2012 ($)
Low penetration in India presents a huge potential going forward
7. Source: AIOCD
MAT August '14 MAT November '06
Rank Market Share Company Rank Market Share Comment
1 6.3% Abbott 13 2.1% Acquisition (Piramal)
2 5.5% Sun Pharma 6 3.2% Organic, +2.3% share
3 4.9% Cipla 3 5.1% -
4 4.4% Zydus 5 3.5% -
5 3.6% Ranbaxy 2 5.1% -
6 3.6% Mankind 16 1.8% Organic, +1.8% share
7 3.4% Alkem 7 3.0% -
8 3.4% Glaxo 1 5.2% -1.8% share
9 3.4% Lupin 9 2.3% -
10 2.9% Pfizer 8 2.6% -
11 2.8% Macleods 25 1.4% Organic, +1.4% share
12 2.8% Emcure 23 1.5% Roche licensing
13 2.6% Intas 17 1.8% Organic, +0.8% share
14 2.5% Sanofi India 10 2.3% -
15 2.5% Aristo 12 2.3% -
Only player to organically breach Top 10 in the past decade
8. FY 95-96 FY 08-09 FY 09-10 FY 10-11 FY 11-12- FY 12-13 FY 13-14 FY 14-15
SALES
$ million
0.8 189 248 317 382 476 560 660
% YOY GR NA 38% 30% 33% 20% 25% 18% 20%
MILESTONES
Company
Founded
First Rank in
Indiaas per
Prescription /
Doctor /
Month
First Rank as
per Value
Generated
from New
Launches
Launched Pet
Mankind
Launched
Lifestar-2
Pharma
Field force
reached to 8500
Field force
reached to
10,000
Field force
reached to
11,000
R & D Set up in
Manesar
Launched in
two states
Entered top 10
Domestic
ranking
Started
International
Operations in
Sri-Lanka
International
horizons
extended to
Nepal, Marutius,
Kenya, Zambia,
Negeria &
Bangladesh
Global
footprints
extended to
Cambodia &
Myanmar
Global
footprints
extended to
Philippines
Journey so far…
9. Source: AIOCD, Company reports
15% 15%
18%
16%
13%
16%
12%
7%
52%
32%
38%
30% 32%
20%
23%
17%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14
Industry vs Makind YoY Growth
Industry Mankind
Exceptional growth of 2.2x Industry…
10. Mankind In Indian Pharma Market
TOP 20 CORPORATES (PRESCIPTION/DOCTOR/MONTH)
RANK CORPORATES P/D/M
1 MANKIND 93
2 CIPLA 66
3 SUN PHARMA 64
4 GLAXOSMITHKLINE 61
5 MACLEODS PHARMACEU. LTD. 57
6 ALKEM LAB. 51
7 MICRO LABS 50
8 ABBOTT HEALTHCARE 49
9 RANBAXY 49
10 DR.REDDY'S LAB. 49
SOURCE IMS HEALTH OCT.2014
Leading the way in prescription per doctor….Leading the way in prescription per doctor….Leading the way in prescription per doctor….Leading the way in prescription per doctor….
11. Source: C MARC July-Aug.2014
4.09%
3.36% 3.33% 3.10%
2.7%
0%
9%
-2%
5%
-3%
8%
2%
-4.00%
-2.00%
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
Mankind Abbott Cipla Glaxo Sun Total Market
Prescription share Growth
Prescription Share and Prescription Growth for CY 12 (%)
Fastest growth in prescriptions a precursor to future growth
12. Deep penetration into rural markets, growth potential from Metros
Source: IMS Jun 13
30%
31%
19%
20%
18%
27%
24%
30%
0%
10%
20%
30%
40%
Metros Class I Class II to VI Rural
Revenue split by town-class (LTM June 2013)
Industry Mankind
14. Source: Company actuals
(In Mn USD)
S. No. Brands Type FY 14-15 YoY Growth
1 Nurokind Acute 47 18%
2 Moxikind Acute 32 10%
3 Mahacef Acute 28 0%
4 Zenflox Acute 26 6%
5 Gudcef Acute 26 11%
6 Manforce Condom OTC 19 14%
7 Amlokind Chronic 19 16%
8 Glimestar Chronic 18 20%
9 Unwanted OTC 15 9%
10 Telmikind Chronic 15 43%
Total top 10 246 13%
As a % of total revenues
Brand oriented growth strategy…
15. Source: AIOCD Mar 14, Company data
8,024
22,727
22,838
53,030
-
20,000
40,000
60,000
80,000
Mar '07 Mar '14
IPM
Chronic Acute
42
507480
2,312
-
750
1,500
2,250
3,000
Mar '07 Mar '14
Mankind
Chronic Acute
Chronic mix % 26% 30% 8% 18%Chronic mix %
(In Rs Cr) (In Rs Cr)
Strong base in Acute, Fast growth through Chronic…
16. Anti Diabetic Segment
$ 31 million
Growth
24%
Field Force Promoting – Anti Diabetic Range
2000
Source: ims-Health Sep.2014, Company actuals
Strong Presence in Anti Diabetic Segment
17. RANK Company Name VALUE ($ MILLION) GROWTH (%)
1 ABBOTT 170 10
2 USV 141 5
3 SUN 83 8
4 SANOFI 80 14
5 NORARTIS 55 18
6 MSD 51 25
7 LUPIN 45 19
8 ELI LILY 38 23
9 MANKIND 30 24
10 MICRO 28 -1
11 INTAS 27 11
Source: ims-Health Sep.2014, Company actuals
Top Companies of Anti Diabetic Segment
18. Cardiac Segment
$ 52 million
Growth
25%
Field Force Promoting – Cardic Range
2000
Source: ims-Health Sep.2014, Company actuals
Strong Presence in Cardiac Segment
19. Source: ims-Health Sep.2014, Company actuals
RANK Company Name VALUE ($ MILLION) GROWTH (%)
1 SUN 120 11
2 ZYDUS 89 2
3 TORRENT 87 -2
4 LUPIN 85 11
5 CIPLA 75 10
6 USV 73 12
7 GLENMARK 68 17
8 MACLEODS 59 16
9 INTAS 56 1
10 EMCURE 55 4
11 MANKIND 52 25
12 ABBOTT 49 -4
Top Companies of Cardiac Segment
20. Source: IMS Jun 13
30%
31%
19%
20%
18%
27%
24%
30%
0%
10%
20%
30%
40%
Metros Class I Class II to VI Rural
Revenue split by town-class (LTM June 2013)
Industry Mankind
Deep penetration in Rural, Strong potential from Metros…
22. 14 World Class Manufacturing Units.
Most units USFDA & WHO-GMP compliant.
Engaged Manufacturing of sterile Injectables , Tablets,
Capsules, Liquid Orals, Creams & Ointments
Infrastructure – Manufacturing Units
23. State-of-the-art Research & Development center at Delhi-
NCR.
Majorly focusing on :
• API Development
• New Drug Delivery System
• Formulation Development
• NCE Development
Infrastructure – R&D Center
25. ASIAASIAASIAASIA AFRICAAFRICAAFRICAAFRICA
Vietnam D R Congo Mozambique Burundi Rwanda
Malawi South Sudan Ghana Ethiopia
CISCISCISCIS LATAMLATAMLATAMLATAM
Kazakhstan Tajikistan Ukraine Brazil Venezuela Ecuador Central
America
Belarus Uzbekistan Kyrgyzstan Columbia Peru Chile Mexico
Shortly Entering
26. Brand driven strategy with 42 brands in leadership position
Pan India coverage through 61 Super distributer & 5000 whole seller.
Field force of 11,000 MRs & Managers.
Focused Doctor centric approach, cover > 4 Lac Doctors covering
Manage a low attrition rate.
KEY DIFFERENTIATORS
27. Won ”Indian Express
Pharma Pulse Award” for
overall performance in
the year 2005.
AWARD FOR OVERALL
PERFORMANCE
AWARD FOR EMERGING
COMPANY
Won “The Emerging Company
of the Year” award at Pharma
Excellence Award, 2007.
AWARD FOR
ENTREPRENEURSHIP
Accorded with “The India
Business Icon (Pharma)”
award by Network 18 for the
year 2011
Awarded for being
the Sustaining Key GrowthSustaining Key GrowthSustaining Key GrowthSustaining Key Growth
Driver for achievingDriver for achievingDriver for achievingDriver for achieving
BusinessBusinessBusinessBusiness Excellence by CitiCitiCitiCiti
Commercial BankCommercial BankCommercial BankCommercial Bank in 2012
Bestowed
as """"EnterpreneurEnterpreneurEnterpreneurEnterpreneur of theof theof theof the
Year"Year"Year"Year" by Ernst & YoungErnst & YoungErnst & YoungErnst & Young
in 2011in 2011in 2011in 2011
AWARDS & RECOGNITION
